Literature DB >> 31791637

Cardiometabolic risk factors and Framingham Risk Score in severely obese patients: Baseline data from DieTBra trial.

Annelisa S A C Santos1, Ana Paula S Rodrigues2, Lorena P S Rosa2, Nizal Sarrafzadegan3, Erika A Silveira2.   

Abstract

BACKGROUND AND AIMS: Little is known about differences of cardiometabolic risk factors (CMRF) and the function of Framingham Risk Score (FRS) within severe obesity, thus we aimed to study not only CMRF and FRS, but to determine significant differences between BMI ranges within severe obesity. METHODS AND
RESULTS: In this baseline analysis of the Traditional Brazilian Diet (DieTBra) Trial, several CMRF were assessed in 150 adult patients in two BMI ranges: 35.0-44.9 kg/m2 (n = 76) and ≥45 kg/m2 (n = 74). Body composition was evaluated by multifrequency bioelectrical impedance analysis to measure the percent of body fat, visceral fat area and waist circumference. Pearson's Chi-squared, Fisher's Exact, Student's t-test, and Mann-Whitney's test were used in the statistical analysis with a 5% significance level. Hypertension, C-reactive protein, systolic and diastolic blood pressure and positive family history for heart diseases were more prevalent in BMI ≥45.0 kg/m2 (p < 0.05). Mean values of waist circumference, body fat %, visceral fat area, and systolic blood pressure were significantly higher in patients with BMI ≥45.0 kg/m2. Regarding the function of FRS, 40.0% of the patients were at high risk. No differences were found for diabetes, lifestyle, lipid parameters, and FRS within different BMI ranges, except for dyslipidemia, significantly higher among participants with BMI 35.0-44.9 kg/m2.
CONCLUSION: BMI >45 kg/m2 was associated with higher prevalence of hypertension, systolic and diastolic blood pressure, C-reactive protein, waist circumference, body fat % and family history of heart diseases, enhancing the risk for the occurrence of cardiovascular diseases.
Copyright © 2019 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Body composition; C-reactive protein; Hypertension; Morbid obesity; Risk factors

Year:  2019        PMID: 31791637     DOI: 10.1016/j.numecd.2019.10.010

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  12 in total

1.  What are the factors associated with sarcopenia-related variables in adult women with severe obesity?

Authors:  Erika Aparecida Silveira; Jacqueline Danesio de Souza; Annelisa Silva E Alves de Carvalho Santos; Andrea Batista de Souza Canheta; Valéria Pagotto; Matias Noll
Journal:  Arch Public Health       Date:  2020-08-03

2.  High prevalence of musculoskeletal pain in individuals with severe obesity: sites, intensity, and associated factors.

Authors:  Carolina Rodrigues Mendonça; Matias Noll; Annelisa Silva E Alves de Carvalho Santos; Ana Paula Dos Santos Rodrigues; Erika Aparecida Silveira
Journal:  Korean J Pain       Date:  2020-07-01

3.  Effects of Extra Virgin Olive Oil (EVOO) and the Traditional Brazilian Diet on Sarcopenia in Severe Obesity: A Randomized Clinical Trial.

Authors:  Erika Aparecida Silveira; Jacqueline Danésio de Souza; Ana Paula Dos Santos Rodrigues; Ricardo M Lima; Camila Kellen de Souza Cardoso; Cesar de Oliveira
Journal:  Nutrients       Date:  2020-05-21       Impact factor: 5.717

4.  Risk Factors Associated with Cardiac Autonomic Modulation in Obese Individuals.

Authors:  Camila Oliveira; Erika Aparecida Silveira; Lorena Rosa; Annelisa Santos; Ana Paula Rodrigues; Carolina Mendonça; Lucas Silva; Paulo Gentil; Ana Cristina Rebelo
Journal:  J Obes       Date:  2020-03-26

5.  Effect of Extra Virgin Olive Oil and Traditional Brazilian Diet on the Bone Health Parameters of Severely Obese Adults: A Randomized Controlled Trial.

Authors:  Camila Kellen de Souza Cardoso; Annelisa Silva E Alves de Carvalho Santos; Lorena Pereira de Souza Rosa; Carolina Rodrigues Mendonça; Priscila Valverde de Oliveira Vitorino; Maria do Rosário Gondim Peixoto; Érika Aparecida Silveira
Journal:  Nutrients       Date:  2020-02-04       Impact factor: 5.717

6.  Identification of the Framingham Risk Score by an Entropy-Based Rule Model for Cardiovascular Disease.

Authors:  You-Shyang Chen; Ching-Hsue Cheng; Su-Fen Chen; Jhe-You Jhuang
Journal:  Entropy (Basel)       Date:  2020-12-13       Impact factor: 2.524

7.  Prevalence of constipation in adults with obesity class II and III and associated factors.

Authors:  Erika Aparecida Silveira; Annelisa Silva E Alves de Carvalho Santos; Jessivane Nascimento Ribeiro; Matias Noll; Ana Paula Dos Santos Rodrigues; Cesar de Oliveira
Journal:  BMC Gastroenterol       Date:  2021-05-12       Impact factor: 3.067

8.  The Effectiveness of Extra Virgin Olive Oil and the Traditional Brazilian Diet in Reducing the Inflammatory Profile of Individuals with Severe Obesity: A Randomized Clinical Trial.

Authors:  Rafael Longhi; Annelisa Silva E Alves de Carvalho Santos; Anallely López-Yerena; Ana Paula Santos Rodrigues; Cesar de Oliveira; Erika Aparecida Silveira
Journal:  Nutrients       Date:  2021-11-19       Impact factor: 5.717

9.  Bone Mineral Density in Severely Obese Women: Health Risk and Health Protective Risk Factors in Three Different Bone Sites.

Authors:  Camila Kellen de Souza Cardoso; Maria do Rosário Gondim Peixoto; Ana Paula Dos Santos Rodrigues; Carolina Rodrigues Mendonça; Cesar de Oliveira; Erika Aparecida Silveira
Journal:  Int J Environ Res Public Health       Date:  2020-09-25       Impact factor: 3.390

10.  Serum and Dietary Vitamin D in Individuals with Class II and III Obesity: Prevalence and Association with Metabolic Syndrome.

Authors:  Erika Aparecida Silveira; Camila Kellen de Souza Cardoso; Letícia de Almeida Nogueira E Moura; Ana Paula Dos Santos Rodrigues; Cesar de Oliveira
Journal:  Nutrients       Date:  2021-06-22       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.